BrainsWay (BWAY) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avita Medical (RCEL) has outperformed BrainsWay (BWAY) over the past year, gaining 138.6% versus a gain of 52.6%. Over five years, BWAY leads with a +197.6% price change compared with -24.9% for RCEL. BrainsWay is the larger company by market cap ($467.7 million vs $403.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BWAY | RCEL |
|---|---|---|
| Share price | $11.62 | $13.05 |
| Market cap | $467.74M | $403.60M |
| 1-day change | -2.27% | +0.46% |
| YTD return | +22.19% | +278.26% |
| 1-year return | +52.59% | +138.57% |
| 5-year return | +197.57% | -24.87% |
| P/E ratio (TTM) | 50.52 | — |
| Forward P/E | 22.93 | — |
| EPS (TTM) | $0.23 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $13.50 |
| 52-week low | $7.14 | $3.22 |
| Distance from 52-week high | -33.22% | -3.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +65.83% | -7.82% |
| Average volume | 119.50K | 444.55K |
| Shares outstanding | 40.25M | 30.93M |
| Employees | 129 | 226 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed BWAY by 86.0 percentage points over the past year.
About BrainsWay
BWAY stock →BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Healthcare · Medical Devices · 129 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Healthcare · Medical Devices · 226 employees
BWAY vs RCEL FAQ
Which is bigger, BrainsWay or Avita Medical?
BrainsWay (BWAY) is larger, with a market capitalization of $467.74M compared with $403.60M for Avita Medical (RCEL).
Which stock has performed better over the past year, BWAY or RCEL?
RCEL returned +138.57% over the past 12 months, compared with +52.59% for BWAY (price return, excluding dividends). Past performance does not predict future results.
Are BrainsWay and Avita Medical in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.